Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
Want to see IMRX full AI Analyst Report?
Total Valuation
Immuneering has a market cap or net worth of $315.08M. The enterprise value is -$43.41B.
Market Cap$315.08M
Enterprise Value-$43.41B
Share Statistics
Immuneering has 64,697,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,697,230
Owned by Insiders9.47%
Owned by Institutions8.01%
Financial Efficiency
Immuneering’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.71%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-26.71%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-1.04M
Employee Count54
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immuneering is ―. Immuneering’s PEG ratio is 0.14.
PE Ratio―
PS Ratio0.00
PB Ratio1.33
Price to Fair Value1.33
Price to FCF-6.37
Price to Operating Cash Flow-4.33
PEG Ratio0.14
Income Statement
In the last 12 months, Immuneering had revenue of 0.00 and earned -56.02M in profits. Earnings per share was -1.27.
Revenue0.00
Gross Profit-698.89K
Operating Income-59.38M
Pretax Income-56.02M
Net Income-56.02M
EBITDA-58.68M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -49.70M and capital expenditures -213.21K, giving a free cash flow of -49.91M billion.
Operating Cash Flow-49.70M
Free Cash Flow-49.91M
Free Cash Flow per Share-0.77
Dividends & Yields
Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change211.46%
50-Day Moving Average5.33
200-Day Moving Average5.74
Relative Strength Index (RSI)38.05
Average Volume (3m)757.80K
Important Dates
Immuneering upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Immuneering as a current ratio of 17.50, with Debt / Equity ratio of 1.81%
Current Ratio17.50
Quick Ratio17.50
Debt to Market Cap<0.01
Net Debt to EBITDA2.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immuneering has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immuneering EV to EBITDA ratio is -2.81, with an EV/FCF ratio of -3.62.
EV to Sales0.00
EV to EBITDA-2.81
EV to Free Cash Flow-3.62
EV to Operating Cash Flow-3.63
Balance Sheet
Immuneering has $156.69B in cash and marketable securities with $3.73B in debt, giving a net cash position of $152.96B billion.
Cash & Marketable Securities$156.69B
Total Debt$3.73B
Net Cash$152.96B
Net Cash Per Share$2.36K
Tangible Book Value Per Share$4.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immuneering is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.00
Price Target Upside205.76% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast40.79%